PT-141 (10 mg Vial) – Dosage Protocol
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Intranasal (IN) Research Summary
- Nasal Spray Output & Conversion Guide
- Recommended Source
- Important Note
- References
Quickstart Highlights
PT-141 (Bremelanotide) is a synthetic peptide and melanocortin receptor agonist (MC3R/MC4R) derived from Melanotan II. It has been studied for its role in modulating central nervous system pathways with desire, arousal, and reward signaling.
Research indicates that PT-141 works by activating melanocortin receptors in the brain, which may influence dopamine activity in areas associated with motivation and response. Unlike some alternatives, its mechanism is centrally acting rather than vascular, making it a distinct compound in this category.
This protocol outlines a once-daily subcutaneous approach with gradual dose escalation, designed to improve tolerance and provide consistent exposure. A practical dilution is used to allow for accurate and simple measurement with standard insulin syringes.
- Reconstitution: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration
- Typical Dose Range: 500–1500 mcg daily (gradual titration recommended)
- Measurement Reference:
- 1 unit (U-100 syringe) = 0.01 mL ≈ 33.3 mcg
- Administration: Subcutaneous injection
- Storage:
- Lyophilized: Store frozen
- Reconstituted: Refrigerate (2–8°C) and avoid repeated freeze–thaw cycles
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Route & Frequency: Administer once daily via subcutaneous injection, typically in the abdomen or thigh. This route offers near-complete bioavailability and is generally better tolerated compared to intranasal delivery. The FDA-approved protocol uses a 1.75 mg subcutaneous dose on an as-needed basis (up to 8 doses per month). In research settings, higher daily doses have also been explored, indicating that consistent daily administration may be well tolerated. This protocol follows a more conservative approach, beginning with lower doses and gradually increasing over time.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water using a sterile syringe
- Inject slowly along the vial wall to minimize foaming
- Gently swirl or roll the vial until fully dissolved (avoid shaking)
- Store refrigerated at 2–8°C, protected from light
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
The following estimates are based on an 8–16 week daily protocol with gradual dose escalation.
Peptide Vials (PT-141, 10 mg each)
- 8 weeks: ~28 mg total usage → approximately 3 vials
- 12 weeks: ~56 mg total usage → approximately 6 vials
- 16 weeks: ~98 mg total usage → approximately 10 vials
Insulin Syringes (U-100)
- Weekly requirement: 7 syringes (one per day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles)
Each vial requires approximately 3.0 mL for reconstitution.
- 8 weeks (3 vials): 9 mL total → 1 × 10 mL bottle
- 12 weeks (6 vials): 18 mL total → 2 × 10 mL bottles
- 16 weeks (10 vials): 30 mL total → 3 × 10 mL bottles
Alcohol Swabs
Use two swabs daily — one for sterilizing the vial and one for the injection site.
- Weekly usage: 14 swabs
- 8 weeks: 112 swabs → recommended 2 × 100-count boxes
- 12 weeks: 168 swabs → recommended 2 × 100-count boxes
- 16 weeks: 224 swabs → recommended 3 × 100-count boxes
Protocol Overview
This protocol outlines a once-daily subcutaneous regimen designed to support consistency through gradual dose escalation.
- Goal: Support sexual desire and arousal via central melanocortin receptor activity
- Duration: 8–12 weeks (extendable up to 16 weeks if needed)
- Dose Range: 500–1500 mcg per day with gradual titration
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for easy measurement
- Storage: Lyophilized (frozen); reconstituted (refrigerated); avoid repeated freeze–thaw cycles
Dosing Protocol
A stepwise titration approach is used to improve tolerance and effectiveness:
- Weeks 1–8: 500 mcg daily
- Weeks 9–12: Increase to 1000 mcg daily
- Weeks 13–16: Increase to 1500 mcg daily (if well tolerated)
- Frequency: Once daily (subcutaneous injection)
- Timing: Any consistent time of day
- Site Rotation: Alternate between abdomen and thighs
Storage Instructions
Proper handling helps maintain peptide stability and effectiveness:
- Lyophilized form: Store at −20°C (−4°F) in a dry, dark environment
- After reconstitution: Refrigerate at 2–8°C (35.6–46.4°F)
- Usage window: Best used within ~30 days
- Avoid repeated freeze–thaw cycles
- Allow vial to reach room temperature before opening to reduce moisture buildup
Important Notes
- Use a new sterile insulin syringe (27–30G) for each injection
- Dispose of all sharps safely after use
- Rotate injection sites to minimize irritation or tissue buildup
- Inject slowly and wait briefly before removing the needle
- Common temporary effects may include nausea, flushing, or mild headache
- Keeping a simple log of dose and injection site can help maintain consistency
How This Works
Bremelanotide is a synthetic analog of α-MSH that acts as a non-selective melanocortin receptor agonist, primarily targeting MC3R and MC4R.
Its primary effects occur in the central nervous system, where activation of these receptors enhances dopamine signaling in key areas such as the nucleus accumbens and medial preoptic region. This activity is associated with increased motivation and arousal.
Unlike PDE5 inhibitors, it does not directly act on blood flow pathways. Instead, its effects are centrally mediated, with downstream influence on physiological responses. Peripheral receptor activity may contribute to effects such as temporary blood pressure changes or skin pigmentation
Potential Benefits & Considerations
Research and clinical observations suggest:
- May support improvements in sexual desire and arousal
- Has shown positive outcomes in clinical populations with reduced desire
- Early findings indicate potential benefits across both men and women
Considerations:
- Most commonly reported effects include nausea, flushing, and headache
- Temporary increases in blood pressure may occur
- Not suitable for individuals with uncontrolled cardiovascular conditions
- Repeated use may lead to mild, reversible skin darkening
Lifestyle Factors
Supporting habits can improve overall outcomes:
- Maintain a balanced diet and regular exercise routine
- Prioritize sleep quality, as it directly impacts hormonal balance
- Manage stress through relaxation techniques or mindfulness practices
- Limit alcohol intake, which may reduce overall effectiveness
Injection Technique
- Clean the vial and injection site with alcohol and allow to dry
- Pinch a small fold of skin and insert the needle at a 45–90° angle
- Inject slowly and steadily (do not aspirate)
- Rotate injection sites regularly (abdomen, thighs)
- Dispose of syringes safely after each use
Intranasal (IN) Research Summary
Bremelanotide was originally developed and studied for intranasal (IN) delivery before the subcutaneous (SC) formulation was selected for FDA approval. The following points summarize findings from peer-reviewed studies. This information is for educational purposes and does not constitute a protocol or dosing recommendation.
Route Studied
- Early-phase clinical trials of PT-141 (bremelanotide) used intranasal delivery via metered-dose nasal spray for both male erectile dysfunction (ED) and female sexual arousal disorder.
Male ED Trials
- Conducted as double-blind, placebo-controlled studies in men with erectile dysfunction.
- Administered doses: 7 mg and 20 mg via nasal spray.
- Results: Statistically significant improvements in erectile function compared to placebo.
Female Sexual Arousal Trials
- Conducted in premenopausal women with female sexual arousal disorder.
- Administered dose: 20 mg intranasally.
- Results: Significant increases in subjective arousal and sexual desire compared to placebo.
Bioavailability Comparison
- Subcutaneous injections achieve approximately 100% bioavailability.
- Intranasal delivery showed lower and more variable absorption between subjects.
- This pharmacokinetic limitation was a key factor in choosing SC injections for the FDA-approved product (Vyleesi).
Blood Pressure Considerations
- Intranasal administration caused more pronounced transient increases in blood pressure than subcutaneous delivery.
- This was another factor influencing the switch to the SC route during development.
Delivery Form & Device
- Early studies used an aqueous solution delivered via a metered-dose nasal spray pump.
- Specific device details, such as volume per actuation, were inconsistently reported.
Adverse Effects
- Nausea was the most common side effect, occurring more frequently at higher doses.
- Nausea could be dose-limiting in some participants.
Pharmacokinetic Variability
- Greater inter-subject variability in Cmax and AUC was observed with intranasal delivery.
- This variability was attributed to differences in nasal mucosal absorption, mucus clearance, and technique.
Key Limitation
- The intranasal route was ultimately not pursued for regulatory approval due to:
- Lower and less predictable bioavailability
- Increased incidence of transient blood pressure elevations
- Higher variability in pharmacokinetics
- Subcutaneous injections provided a more reliable and consistent route for clinical use.
Nasal Spray Output & Conversion Guide
Important: The amount delivered per spray depends entirely on the specific nasal spray device. Output can vary based on the manufacturer, design, and priming. Always confirm the volume per actuation using manufacturer specifications or direct measurement.
This section is for calculation purposes only and does not represent a dosing recommendation.
Basic Calculation Framework
To determine how much peptide is delivered per spray, use:
Concentration (mcg/mL): Final solution strength after reconstitution
(Convert if needed: mg/mL × 1000 = mcg/mL)Spray Output (mL per actuation): Volume delivered per pump
Formula
mcg per spray = concentration × spray volume
Optional Unit-Based Conversion (U-100 Reference)
If using insulin-style “units” as a volume reference:
1 mL = 100 units
Spray volume (mL) = units ÷ 100
Updated Formula
mcg per spray = concentration × (units ÷ 100)
Calculation Table (Template)
| Concentration (mcg/mL) | Spray Output (mL) | mcg per Spray | Sprays per mL | Total Sprays |
|---|---|---|---|---|
| A | B | A × B | 1 ÷ B | Total mL ÷ B |
| C | D | C × D | 1 ÷ D | Total mL ÷ D |
Worked Examples (For Understanding Only)
Example 1 (mL-based device):
Concentration: 3333 mcg/mL (10 mg in 3 mL)
Spray output: 0.10 mL
→ mcg per spray = 3333 × 0.10 = 333.3 mcg
→ Sprays per mL = 10
→ Total sprays (3 mL) = 30 sprays
Example 2 (unit-based device):
Concentration: 3333 mcg/mL
Device output: 13 units
→ Volume per spray = 13 ÷ 100 = 0.13 mL
→ mcg per spray = 3333 × 0.13 = 433.3 mcg
→ Sprays per mL ≈ 7.7
→ Total sprays (3 mL) ≈ 23 sprays
Final Note
These examples are based on a 10 mg / 3 mL reconstitution for demonstration only.
Actual output depends on the specific device, so accurate calibration is essential.
Recommended Source
We recommend Fit Aminos for high-purity research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. PT-141 – 10mg remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
ScienceDirect
— Bremelanotide: pharmacology, toxicology, and therapeutic overview (active metabolite of Melanotan II)
ResearchGate (2022)
— Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials
Mayo Clinic
— Bremelanotide (subcutaneous route): side effects, dosage, and precautions
MedlinePlus
— Patient instructions for subcutaneous injections: site rotation and technique